Phase 4 N=1,952 Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 2 N=64 Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
Interpandemic Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Phase 4 N=1,000 A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Influenza Vaccines
Primary: Geometric Mean Titers (GMTs) of Anti-H3 and B Strains — 369.6; 331.2; 269.6; 245.0 Titer
Phase 1 N=60 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)
Influenza, Human
Primary: Number of Participants With Immediate Adverse Events — 0; 0 participants
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Phase 3 N=135 Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
Seasonal Influenza Vaccine
Primary: Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV). — 22; 23; 624; 199 Titer
Phase 4 N=200 Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® or Fluzone® Intradermal or Fluzone® High-Dose…
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Influenza
Primary: Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent…
Phase 1 N=241 Flublok or Fluzone With Advax-CpG55.2 or AF03
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
Phase 2 N=600 A Study of Influenza Virus Vaccines in Children and Adults
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone® Trivalent…
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
Influenza
Primary: Percentage of Participants Reporting Solicited Injection-site and Solicited Systemic Reactions Following Vaccination With the 2014-2015 Formulation of Fluzone®…
Phase 4 N=984 Inactivated Influenza Via Jet Injection
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
Phase 2 N=63 Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
Seasonal Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
N/A N=179 Open-Label Influenza Vaccine Evaluation
Immune Response
Primary: HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination — 175; 117; 144; 118 Titer
Phase 3 N=2,680 Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
Influenza
Primary: 1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c — 60.7; 59.6; NA; 302.8 Titer
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
Phase 3 N=1,801 Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
Influenza
Primary: Hemagglutination Inhibition Antibody (HIA) Titer for Each of the Three Antigens Contained in the Vaccine — 269.7; 337.3; 288.5; 297.1 Titers
Phase 2 N=729 Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Influenza · Orthomyxoviruses · Myxovirus Infection
Primary: Summary of the Pre- and Post-Vaccination Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigens. — 25.9; 26.4; 26.6; 184.8 Titers
N/A N=87,665 From Innovation to Solutions: Childhood Influenza Vaccination Planning
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
N/A N=193 Immune Responses Induced by Different Licensed Influenza Vaccines
Immune Response
Primary: T Cell Responses Following Immunization — 1.5; 1.7; 1.9; 1.6 fold change
Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3
Influenza, Human
Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants
Phase 3 N=2,235 Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
Influenza
Primary: Number of Subjects Reporting Solicited Adverse Events After One Dose of Cell Culture-derived or the Egg-derived Influenza Vaccine — 78; 73; 47; 51 Participants
Phase 4 N=208 Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
Influenza
Primary: Number of Participants With Solicited Injection-Site or Systemic Reactions After Receipt of the 2015-2016 Formulation of Fluzone Quadrivalent, Fluzone Intradermal…
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
Phase 3 N=1,561 Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects
Prophylaxis: Influenza
Primary: Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots. — 667; 738; 655; 466 Titers
Phase 4 N=40 Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Asthmatic
Primary: Feasibility Benchmark: Number of Parents That Complete the Memory Aid 1. — 35 Participants
Phase 2 N=209 Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
Influenza
Primary: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous Influenza Strain on Day 0 — 87.5704; 71.2385; 69.1840; 60.7941…
Phase 2 N=256 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
Influenza, Human
Primary: Percentage of Participants Reporting Local Reactions After Vaccination 1: Substudy A — 0; 0; 0; 0 Percentage of participants